Academic Journals Database
Disseminating quality controlled scientific knowledge

Glioblastoma Multiforme Therapy and Mechanisms of Resistance

Author(s): Yulian P. Ramirez | Jessica L. Weatherbee | Richard T. Wheelhouse | Alonzo H. Ross

Journal: Pharmaceuticals
ISSN 1424-8247

Volume: 6;
Issue: 12;
Start page: 1475;
Date: 2013;
Original page

Keywords: angiogenesis | autophagy | imidazotetrazine | MGMT | DNA repair | temozolomide | cancer stem cells

Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona